Human Volunteers Clinical Trial
Official title:
A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds
Background:
- Some types of cancer, like cancer of the esophagus, are difficult to detect at an early
stage. A possible detection method involves collecting breath samples to look for chemicals
that may be signs of cancer. However, more research is needed to determine how different
chemicals appear in different breath samples. This study will involve healthy volunteers.
Objectives:
- To study chemicals appearing in breath samples of healthy volunteers.
Eligibility:
- Healthy volunteers between 30 and 60 years of age.
Design:
- Participants will fast overnight (midnight to morning) and then provide two breath
samples taken 5 minutes apart.
- Breath samples will be collected on days 1, 49, and 98 of the study
Background:
Although breath tests are common for specific uses where the biomarker is highly concentrated
(e .g. alcohol, urea for Helicobacter prylori infection), lower concentration compounds in
the breath can also provide information on exogenous exposures and endogenous metabolic
processes.
Employing standardized collection techniques and high sensitivity measurement technologies
have shown that breath profiles can accurately identify people with diseases such as breast
cancer and lung cancer.
Breath profiling technologies have great potential as non-invasive tools for diagnosis and
risk stratification of precancerous disease as well as elucidation of the causes of cancer.
Prior to using breath profiles for these purposes it is essential to assess how much of the
breath profile and which parts of the breath profile are relatively stable over a period of
time.
Objectives:
The primary objective of this pilot study is to assess the intra-individual variability of
breath profiles sampled over a period of 98 days.
Eligibility:
DCEG volunteers aged 30-60 years, inclusive.
Design:
Pilot study.
Five DCEG volunteers will be enrolled for this study.
We will assess breath profiles sampled in duplicate at three time periods (days 1, 49 and
98).
We will calculate a coefficients of variation (CV) to determine the proportion and parts of
the breath profile which have values less than 10% when collected on the same day,49 days
apart, and 98 days apart.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03093506 -
Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance
|
Early Phase 1 | |
| Completed |
NCT00526968 -
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
|
Phase 1 | |
| Completed |
NCT03277456 -
A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1
|
Early Phase 1 | |
| Completed |
NCT02922933 -
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01468714 -
A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01464385 -
Nutrition Beverage Tolerance Study
|
Phase 2 | |
| Completed |
NCT01452425 -
In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome
|
Phase 1 | |
| Completed |
NCT02922946 -
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
|
Phase 1 | |
| Completed |
NCT00254449 -
Effect of NGX-4010 on ENFD and Sensory Function
|
Phase 1 | |
| Completed |
NCT01618877 -
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01618903 -
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
|
Phase 1 | |
| Completed |
NCT00752466 -
A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately
|
Phase 1 | |
| Completed |
NCT00166933 -
Minimal Erythema Dose of UV-B in Normal Population of Taiwan
|
N/A | |
| Completed |
NCT05519514 -
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects
|
Phase 1 | |
| Completed |
NCT01776437 -
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
|
Phase 1 | |
| Completed |
NCT01445860 -
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00744809 -
TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.
|
Phase 1 | |
| Unknown status |
NCT00743977 -
Bioequivalence of Phenazopyridine HCl in Healthy Volunteers
|
N/A |